Please login to the form below

Not currently logged in
Email:
Password:

Immunomedics

This page shows the latest Immunomedics news and features for those working in and with pharma, biotech and healthcare.

Immunomedics craters after FDA rejects breast cancer ADC

Immunomedics craters after FDA rejects breast cancer ADC

Regulator wants to see more data on manufacturing. Shares in Immunomedics have gone into steep decline after the FDA rejected its breast cancer drug sacituzumab govitecan. ... Immunomedics’ management also expressed surprise at the rejection,

Latest news

  • Bluebird and Celgene BCMA CAR-T kicks off ASCO Bluebird and Celgene BCMA CAR-T kicks off ASCO

    Immunomedics will present phase I/II result of its Trop-2-targeting sacituzumab govitecan (IMMU-132) in breast cancer - which prompted an investor revolt when the biotech’s former management tried

  • Seattle Genetics claims key US approval for Adcetris Seattle Genetics claims key US approval for Adcetris

    The approval is also important for Seattle after its aborted $2bn deal to license Immunomedics’ IMMU-132, another ADC drug for triple-negative breast cancer (TNBC), which was scuppered by a ... shareholder and claimed the jobs of Immunomedics’ CEO

  • Activists torpedo Immunomedics deal with Seattle Genetics Activists torpedo Immunomedics deal with Seattle Genetics

    Immunomedics shareholders - pointing out that the company has failed to bring any products to market in its 35-year history. ... Now, its would-be partner has decided to duck out of the messy business although it retains a stake in Immunomedics.

  • Move on Immunomedics board puts Seattle Genetics deal in doubt Move on Immunomedics board puts Seattle Genetics deal in doubt

    An acrimonious battle between the current management of Immunomedics and activist investor group venBio came to a head on Friday after shareholders elected all four of the latter's candidates to ... and punishing Immunomedics for failing to bring any

  • Seattle Genetics signs $2bn deal for Immunomedics' cancer drug Seattle Genetics signs $2bn deal for Immunomedics' cancer drug

    Immunomedics has signed up Seattle Genetics as the licensee for its triple-negative breast cancer (TNBC) drug IMMU-132, getting $300m upfront and another $1.7bn in possible milestone payments. ... Immunomedics' chief executive Cynthia Sullivan said she

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... metastases.  The acquisition helps to bolster Seattle's late stage pipeline and comes at a lower price tag than

  • Deal Watch March 2017 Deal Watch March 2017

    In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... The activist investor venBio, which has recently gained

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.

  • Pharma deals during October 2013 Pharma deals during October 2013

    The dispute between the parties concerns development delays that Immunomedics argued were material breach of the agreement. ... there may be potentially good prospects for Immunomedics to find another partner once the dust has settled. .

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics